Performant Financial Corporation Announces Financial Results for Second Quarter 2024

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Insights

Performant Financial's Q2 2024 results show mixed signals. While healthcare revenues grew 17% year-over-year to $27.9 million, the company still reported a net loss of $3.0 million. However, this loss narrowed from $4.0 million in the prior year period, indicating some improvement.

The adjusted EBITDA of $0.5 million, compared to -$1.3 million last year, suggests progress in operational efficiency. The company's focus on commercial implementations (20 in 2024) could drive future growth, potentially contributing $9 million in annualized revenue.

Despite the ongoing losses, management's reiteration of 2024 guidance ($117-122 million in healthcare revenues) shows confidence in their growth trajectory. Investors should monitor the company's ability to translate revenue growth into profitability in coming quarters.

Performant's Q2 results highlight its strong position in the healthcare payment integrity market. The 17% growth in healthcare revenues, particularly in claims-based ($13.7 million) and eligibility-based services ($14.3 million), indicates increasing demand for these solutions.

The company's success in implementing 10 commercial clients in Q2 alone suggests a robust pipeline and effective sales strategy. The continued ramp-up of the CMS RAC Region 2 contract is another positive, demonstrating Performant's ability to secure and execute large government contracts.

However, the ongoing net losses raise questions about the scalability of their business model. Investors should watch for improvements in operational efficiency and the impact of the company's initiatives to drive productivity in future quarters.

08/07/2024 - 04:00 PM

PLANTATION, Fla.--(BUSINESS WIRE)-- Performant Financial Corporation (Nasdaq: PFMT), a leading provider of healthcare payment integrity services, today reported the following financial results for its second quarter ended June 30, 2024:

Second Quarter Financial Highlights

Healthcare revenues of $27.9 million, compared to $23.9 million in the prior year period, an increase of approximately 17%.
Total revenues of $29.4 million, compared to total revenues of $25.5 million in the prior year period.
Net loss of $3.0 million, or $(0.04) per diluted share, compared to net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period.
Adjusted EBITDA of $0.5 million, compared to $(1.3) million in the prior year period.
Adjusted net loss was $2.0 million, or $(0.03) per diluted share, compared to adjusted net loss of $3.2 million, or $(0.04) per diluted share, in the prior year period.

Second Quarter 2024 Results

Healthcare revenues in the second quarter of 2024 were $27.9 million, an increase of approximately 17% from $23.9 million in the prior year period. Total revenues in the second quarter were $29.4 million, an increase of 15% from total revenues of $25.5 million in the prior year period. Within healthcare, claims-based services revenue in the second quarter of 2024 was $13.7 million, while revenue from eligibility-based services in the second quarter was $14.3 million.

“Our healthcare revenue once again enjoyed strong double-digit year over year growth, driven by an increase in commercial client implementations and the continued ramp under our CMS RAC Region 2 contract," stated Simeon Kohl, CEO of Performant. "We continue to fuel future growth with 10 commercial implementations in the second quarter. We have implemented 20 commercial programs during 2024, which are estimated to contribute approximately $9 million in revenue at annualized steady state. Our larger initiatives to drive efficiency and productivity are progressing as planned, with positive early results. We remain committed to delivering innovative solutions and long-term value to our clients and stakeholders. I am pleased with the results we have driven in the first half of the year and the progress made on our operational and organization initiatives," Kohl further remarked.

Revenues from our customer care / outsourced services in the second quarter were $1.4 million, down from $1.5 million in the prior year period.

Net loss for the second quarter was $3.0 million, or $(0.04) per diluted share, compared to a net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the second quarter was $0.5 million as compared to $(1.3) million in the prior year period. Adjusted net loss for the second quarter was $2.0 million, or $(0.03) per share on a diluted basis, compared to adjusted net loss of $3.2 million, or $(0.04) per diluted share, in the prior year period.

“The strong results we delivered in the second quarter and first half of the year are a testament to the growth of our organization,” said Rohit Ramchandani, Chief Financial Officer. “We delivered strong revenue and profitability, fueled future growth with double-digit implementations, and simultaneously invested in efficiency initiatives. With second quarter results ahead of expectations, we are encouraged to reiterate our expectation of 2024 healthcare revenues in the range of $117 million to $122 million, total Company revenues to be in the range of $124 million to $129 million, and adjusted EBITDA in the range of $4 million to $5 million," Ramchandani further commented.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking non-GAAP adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items. These items include, but are not limited to, impacts associated with interest expense, and depreciation and amortization expenses.

Earnings Conference Call

The Company will hold a conference call to discuss its second quarter 2024 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. To dial into the call you can dial 877-737-7051 or 201-689-8878 or preregister through the below link. After registering, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 13747328. The telephonic replay will be available approximately three hours after the call, through August 14, 2024.

About Performant Healthcare Solutions

Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.

To learn more, please visit http://www.performanthealth.com

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), adjusted EBITDA in 2024 and beyond, our commercial client growth strategy, our estimated revenue from commercial programs implemented in the first half of 2024, and the expected benefits of the RecordsOne technology asset acquisition. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to generate revenue following long implementation periods associated with new customer contracts; client relationships and the Company’s ability to maintain such client relationships; many of the Company’s customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes; anticipated trends and challenges in the Company’s business and competition in the markets in which it operates; the Company’s indebtedness and compliance, or failure to comply, with restrictive covenants in the Company’s credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company’s ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company’s ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health pandemics such as COVID-19 on the Company’s business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company’s operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company’s third-party vendors and subcontractors; the adaptability of the Company’s technology platform to new markets and processes; the Company’s ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company’s growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company’s ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company’s ability to comply with and adapt to industry regulations and compliance demands.

More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2023 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES Consolidated Balance Sheets (In thousands, except par value amounts)

	June 30, 2024			December 31, 2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	10,424		$	7,252
Restricted cash		—			81
Trade accounts receivable, net of allowance for credit losses		14,070			17,584
Contract assets		9,928			10,879
Prepaid expenses and other current assets		3,610			3,651
Income tax receivable		106			335
Total current assets		38,138			39,782
Property, equipment, and software, net		14,685			9,724
Goodwill		47,372			47,372
Debt issuance costs		531			631
Right-of-use assets		935			531
Other assets		776			990
Total assets	$	102,437		$	99,030
Liabilities and Stockholders’ Equity
Current liabilities:
Accrued salaries and benefits		8,337			7,924
Accounts payable		888			727
Other current liabilities		1,868			2,385
Contract liabilities		848			493
Estimated liability for appeals and disputes		1,223			601
Deferred asset acquisition payments		723			—
Lease liabilities		485			250
Total current liabilities		14,372			12,380
Long-term loan payable		8,000			5,000
Deferred asset acquisition payments		3,068			—
Lease liabilities		467			295
Other liabilities		664			648
Total liabilities		26,571			18,323
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value. Authorized, 500,000 shares at June 30, 2024 and December 31, 2023 respectively; issued and outstanding 77,190 and 76,920 shares at June 30, 2024 and December 31, 2023, respectively		8			8
Additional paid-in capital		148,173			146,001
Accumulated deficit		(72,315	)		(65,302	)
Total stockholders’ equity		75,866			80,707
Total liabilities and stockholders’ equity	$	102,437		$	99,030

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Revenues	$	29,362		$	25,485		$	56,696		$	51,214
Operating expenses:
Salaries and benefits		24,534			21,710			47,755			44,159
Other operating expenses		7,569			7,376			15,603			14,445
Total operating expenses		32,103			29,086			63,358			58,604
Loss from operations		(2,741	)		(3,601	)		(6,662	)		(7,390	)
Gain on sale of certain recovery contracts		—			—			—			3
Interest expense		(300	)		(351	)		(486	)		(765	)
Interest income		61			—			167			—
Loss before provision for income taxes		(2,980	)		(3,952	)		(6,981	)		(8,152	)
Provision for income taxes		16			21			32			42
Net loss	$	(2,996	)	$	(3,973	)	$	(7,013	)	$	(8,194	)
Net loss per share
Basic	$	(0.04	)	$	(0.05	)	$	(0.09	)	$	(0.11	)
Diluted	$	(0.04	)	$	(0.05	)	$	(0.09	)	$	(0.11	)
Weighted average shares
Basic		76,975			75,752			76,925			75,629
Diluted		76,975			75,752			76,925			75,629

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands) (Unaudited)

	Six Months Ended June 30,
		2024			2023
Cash flows from operating activities:
Net loss	$	(7,013	)	$	(8,194	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Loss on disposal of assets		29			36
Depreciation and amortization		3,317			2,512
Right-of-use assets amortization		224			1,455
Stock-based compensation		2,262			1,686
Interest expense from debt issuance costs		115			122
Gain on sale of certain recovery contracts		—			(3	)
Changes in operating assets and liabilities:
Trade accounts receivable		3,514			3,004
Contract assets		951			4,513
Prepaid expenses and other current assets		41			683
Income tax receivable		229			(53	)
Other assets		208			25
Accrued salaries and benefits		413			(820	)
Accounts payable		161			(67	)
Contract liabilities and other current liabilities		(162	)		(658	)
Estimated liability for appeals and disputes		622			(299	)
Lease liabilities		(221	)		(1,691	)
Other liabilities		16			14
Net cash provided by operating activities		4,706			2,265
Cash flows from investing activities:
Purchase of property, equipment, and software		(4,510	)		(2,339	)
Proceeds from sale of certain recovery contracts		—			3
Net cash used in investing activities		(4,510	)		(2,336	)
Cash flows from financing activities:
Repayment of long-term loan payable		—			(8,000	)
Debt issuance costs paid		(15	)		(274	)
Taxes paid related to net share settlement of stock awards		(90	)		(57	)
Borrowings from revolving loan		3,000			—
Net cash provided by (used in) financing activities		2,895			(8,331	)
Net increase (decrease) in cash, cash equivalents and restricted cash		3,091			(8,402	)
Cash, cash equivalents and restricted cash at beginning of period		7,333			23,465
Cash, cash equivalents and restricted cash at end of period	$	10,424		$	15,063
Reconciliation of the Consolidated Statements of Cash Flows to the Consolidated Balance Sheets:
Cash and cash equivalents	$	10,424		$	14,982
Restricted cash		—			81
Total cash, cash equivalents and restricted cash at end of period	$	10,424		$	15,063
Non-cash investing activities:
Deferred asset acquisition payments	$	3,791		$	—
Supplemental disclosures of cash flow information:
Cash (received) paid for income taxes	$	(151	)	$	143
Cash paid for interest	$	252		$	721

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES Reconciliation of Non-GAAP Results (In thousands, except per share amount) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
	(in thousands)						(in thousands)
Adjusted EBITDA:
Net income (loss)	$	(2,996	)	$	(3,973	)	$	(7,013	)	$	(8,194	)
Provision for income taxes		16			21			32			42
Interest expense ⁽¹⁾		300			351			486			765
Interest income		(61	)		—			(167	)		—
Stock-based compensation		1,305			888			2,262			1,686
Depreciation and amortization		1,919			1,265			3,317			2,512
Severance expenses ⁽³⁾		50			119			386			182
Other		15			30			15			29
Adjusted EBITDA	$	548		$	(1,299	)	$	(682	)	$	(2,978	)

	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
	(in thousands)						(in thousands)
Adjusted Net Income (Loss):
Net income (loss)	$	(2,996	)	$	(3,973	)	$	(7,013	)	$	(8,194	)
Stock-based compensation		1,305			888			2,262			1,686
Amortization of debt issuance costs ⁽²⁾		57			87			115			122
Severance expenses ⁽³⁾		50			119			386			182
Other		15			30			15			29
Tax adjustments⁽⁴⁾		(393	)		(309	)		(764	)		(555	)
Adjusted net income (loss)	$	(1,962	)	$	(3,158	)	$	(4,999	)	$	(6,730	)

	Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
	(in thousands)						(in thousands)
Adjusted Net Income (Loss) Per Diluted Share:
Net income (loss)	$	(2,996	)	$	(3,973	)	$	(7,013	)	$	(8,194	)
Plus: Adjustment items per reconciliation of adjusted net income (loss)		1,034			815			2,014			1,464
Adjusted net income (loss)	$	(1,962	)	$	(3,158	)	$	(4,999	)	$	(6,730	)
Adjusted net income (loss) per diluted share	$	(0.03	)	$	(0.04	)	$	(0.06	)	$	(0.09	)
Diluted average shares outstanding		76,975			75,752			76,925			75,629

(1)	Represents interest expense and amortization of debt issuance costs related to our Credit Agreement.
(2)	Represents amortization of debt issuance costs related to our Credit Agreement.
(3)	Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.
(4)	Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Quarterly and Annual Revenues
(In thousands)
(Unaudited)

We are providing the following historical breakdown of the quarterly and annual revenue contributions under the contribution breakdowns of our healthcare revenue results for the six months ended June 30, 2024, and for the years ended December 31, 2023 and 2022:

	Three Months Ended				Six Months Ended
	March 31, 2024		June 30, 2024		June 30, 2024
					(in thousands)
Eligibility-based	$	13,388	$	14,264	$	27,652
Claims-based		12,412		13,661		26,073
Healthcare Total		25,800		27,925		53,725
Customer Care / Outsourced Services		1,534		1,437		2,971
Total	$	27,334	$	29,362	$	56,696

	Three Months Ended								Year Ended
	March 31, 2023		June 30, 2023		September 30, 2023		December 31, 2023		December 31, 2023
	(in thousands)
Eligibility-based	$	12,480	$	14,131	$	18,165	$	16,403	$	61,179
Claims-based		10,412		9,798		10,325		14,730		45,265
Healthcare Total		22,892		23,929		28,490		31,133		106,444
Recovery		19		14				—		33
Customer Care / Outsourced Services		2,818		1,542		1,472		1,434		7,266
Total	$	25,729	$	25,485	$	29,962	$	32,567	$	113,743

	Three Months Ended								Year Ended
	March 31, 2022		June 30, 2022		September 30, 2022		December 31, 2022		December 31, 2022
	(in thousands)
Eligibility-based	$	14,214	$	12,417	$	13,142	$	13,511	$	53,284
Claims-based		9,150		9,339		10,377		12,516		41,382
Healthcare Total		23,364		21,756		23,519		26,027		94,666
Recovery		118		7		41		75		241
Customer Care / Outsourced Services		3,601		3,918		3,618		3,140		14,277
Total	$	27,083	$	25,681	$	27,178	$	29,242	$	109,184

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807227296/en/

Jon Bozzuto

Investor Relations

925-960-4988

investors@performantcorp.com

Source: Performant Financial Corporation

FAQ

What was Performant Financial's (PFMT) healthcare revenue in Q2 2024?

Performant Financial's healthcare revenue in Q2 2024 was $27.9 million, representing a 17% increase from the prior year period.

How many commercial programs did Performant (PFMT) implement in 2024?

Performant implemented 20 commercial programs during 2024, with 10 of these implemented in the second quarter alone.

What is Performant's (PFMT) revenue guidance for 2024?

Performant reiterated its 2024 guidance, expecting healthcare revenues of $117-122 million and total company revenues of $124-129 million.

What was Performant's (PFMT) adjusted EBITDA for Q2 2024?

Performant's adjusted EBITDA for Q2 2024 was $0.5 million, an improvement from $(1.3) million in the prior year period.

Performant Financial Corporation Announces Financial Results for Second Quarter 2024

Insights

FAQ

What was Performant Financial's (PFMT) healthcare revenue in Q2 2024?

How many commercial programs did Performant (PFMT) implement in 2024?

What is Performant's (PFMT) revenue guidance for 2024?

What was Performant's (PFMT) adjusted EBITDA for Q2 2024?

NASDAQ:PFMT

PFMT Rankings

PFMT Latest News

PFMT Stock Data

Trending News

Performant Financial Corporation Announces Financial Results for Second Quarter 2024

Insights

Financial Analyst neutral

Healthcare Industry Analyst positive

FAQ

What was Performant Financial's (PFMT) healthcare revenue in Q2 2024?

How many commercial programs did Performant (PFMT) implement in 2024?

What is Performant's (PFMT) revenue guidance for 2024?

What was Performant's (PFMT) adjusted EBITDA for Q2 2024?

NASDAQ:PFMT

PFMT Rankings

PFMT Latest News

PFMT Stock Data